Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of GSK1605786A for moderately to severely active Crohn's disease
NL-OMON36819Phase 3Not yet recruiting
- Sponsor
- GSK
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vercirnon in Crohn's disease (3 arms), sponsored by GSK. Primary endpoint: Primary efficacy endpoint. Planned start Jan 2011; status: not yet recruiting.
02
Drugs
vercirnon
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON36819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36819.